• 1
    Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006; 295: 2164-2167.
  • 2
    Chaplin JM, O'Brien CJ, McNeil EB, Haghighi K. Application of prognostic scoring systems in differentiated thyroid carcinoma. Aust N Z J Surg. 1999; 69: 625-628.
  • 3
    Palme CE, Waseem Z, Raza SN, Eski S, Walfish P, Freeman JL. Management and outcome of recurrent well-differentiated thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2004; 130: 819-824.
  • 4
    Mariotti S, Barbesino G, Caturegli P, et al. Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal? J Clin Endocrinol Metab. 1995; 80: 468-472.
  • 5
    Phan HT, Jager PL, van der Wal JE, et al. The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur J Endocrinol. 2008; 158: 77-83.
  • 6
    Scopsi L, Collini P, Sampietro G, Boracchi P, Pilotti S. Prognostic impact of thyroid lymphocytic infiltration in patients with medullary thyroid carcinoma. Thyroid. 1996; 6: 613-617.
  • 7
    Modi J, Patel A, Terrell R, Tuttle RM, Francis GL. Papillary thyroid carcinomas from young adults and children contain a mixture of lymphocytes. J Clin Endocrinol Metab. 2003; 88: 4418-4425.
  • 8
    Gupta S, Patel A, Folstad A, et al. Infiltration of differentiated thyroid carcinoma by proliferating lymphocytes is associated with improved disease-free survival for children and young adults. J Clin Endocrinol Metab. 2001; 86: 1346-1354.
  • 9
    Souza SL, Montalli Da Assumpcao LV, Ward LS. Impact of previous thyroid autoimmune diseases on prognosis of patients with well-differentiated thyroid cancer. Thyroid. 2003; 13: 491-495.
  • 10
    Hoffmann TK, Dworacki G, Tsukihiro T, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002; 8: 2553-2562.
  • 11
    Whiteside TL. Apoptosis of immune cells in the tumor microenvironment and peripheral circulation of patients with cancer: implications for immunotherapy. Vaccine. 2002; 20(suppl 4): A46-A51.
  • 12
    Tsukishiro T, Donnenberg AD, Whiteside TL. Rapid turnover of the CD8(+)CD28(−) T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol Immunother. 2003; 52: 599-607.
  • 13
    Trauth BC, Klas C, Peters AM, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 1989; 245: 301-305.
  • 14
    Fulda S, Debatin KM. Exploiting death receptor signaling pathways for tumor therapy. Biochim Biophys Acta. 2004; 1705: 27-41.
  • 15
    Krammer PH. CD95′s deadly mission in the immune system. Nature. 2000; 407: 789-795.
  • 16
    de Jong S, Timmer T, Heijenbrok FJ, de Vries EG. Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastasis Rev. 2001; 20: 51-56.
  • 17
    Izbicka E, Streeper RT, Michalek JE, Louden CL, Diaz A3rd, Campos DR. Plasma biomarkers distinguish non-small cell lung cancer from asthma and differ in men and women. Cancer Genomics Proteomics. 2012; 9: 27-35.
  • 18
    Zurita AJ, Jonasch E, Wang X, et al. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2012; 23: 46-52.
  • 19
    Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012; 13: 827-837.
  • 20
    Contal C, O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Computational Stat Data Anal. 1999; 30: 253-270.
  • 21
    Hedayati M, Yaghmaei P, Pooyamanesh Z, Zarif Yeganeh M, Hoghooghi Rad L. Leptin: a correlated Peptide to papillary thyroid carcinoma [serial online]? J Thyroid Res 2011; 211: 832163.
  • 22
    Akinci M, Kosova F, Cetin B, Aslan S, Ari Z, Cetin A. Leptin levels in thyroid cancer. Asian J Surg. 2009; 32: 216-223.
  • 23
    Singh SK, Grifson JJ, Mavuduru RS, Agarwal MM, Mandal AK, Jha V. Serum leptin: a marker of prostate cancer irrespective of obesity. Cancer Biomark. 2010; 7: 11-15.
  • 24
    Hsing AW, Chua S Jr, Gao YT, et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst. 2001; 93: 783-789.
  • 25
    Artac M, Bozcuk H, Kiyici A, Eren OO, Boruban MC, Ozdogan M. Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs) [published online ahead of print December 28, 2011]. Breast Cancer. 2011.
  • 26
    Wu MH, Chou YC, Chou WY, et al. Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer. 2009; 100: 578-582.
  • 27
    Miyoshi Y, Funahashi T, Tanaka S, et al. High expression of leptin receptor mRNA in breast cancer tissue predicts poor prognosis for patients with high, but not low, serum leptin levels. Int J Cancer. 2006; 118: 1414-1419.
  • 28
    Cheng SP, Chi CW, Tzen CY, et al. Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma. Surgery. 2010; 147: 847-853.
  • 29
    Uddin S, Bavi P, Siraj AK, et al. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. Endocr Related Cancer. 2010; 17: 191-202.
  • 30
    Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res. 1999; 5: 3529-3533.
  • 31
    Konno R, Takano T, Sato S, Yajima A. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies. Clin Cancer Res. 2000; 6: 3576-3580.
  • 32
    Mizutani Y, Yoshida O, Bonavida B. Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J Urol. 1998; 160: 571-576.
  • 33
    Mizutani Y, Hongo F, Sato N, Ogawa O, Yoshida O, Miki T. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer. 2001; 92: 287-293.
  • 34
    Whiteside TL. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother. 1999; 48: 346-352.
  • 35
    Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer. 2001; 85: 1047-1054.
  • 36
    Mitsiades N, Poulaki V, Mastorakos G, et al. Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. J Clin Endocrinol Metab. 1999; 84: 2924-2932.
  • 37
    Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2000; 60: 4122-4129.
  • 38
    Ahmad M, Shi Y. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention. Oncogene. 2000; 19: 3363-3371.
  • 39
    Takeda K, Ohara E, Kaneda T, Hashimoto K, Sasaki M. Increased serum soluble Fas ligand in hyperthyroid Graves' disease [article in Japanese]. Rinsho Byori. 1999; 47: 961-965.
  • 40
    Toyozaki T, Hiroe M, Saito T, et al. Levels of soluble Fas in patients with myocarditis, heart failure of unknown origin, and in healthy volunteers. Am J Cardiol. 1998; 81: 798-800.
  • 41
    Toyozaki T, Hiroe M, Tanaka M, Nagata S, Ohwada H, Marumo F. Levels of soluble Fas ligand in myocarditis. Am J Cardiol. 1998; 82: 246-248.